SEARCH

SEARCH BY CITATION

References

  • 1
    Choo QL, Kuo G, Weiner A, Overby RL, Bradley DW, Houghton M. Isolation of a cDNA clone derived from blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244:359362. MEDLINE
  • 2
    Alter HJ. To C or not to C: these are the questions. Blood 1995; 85:16811695. MEDLINE
  • 3
    Fried MW, Hoofnagle JH. Therapy of hepatitis C. Semin Liver Dis 1995; 15:8291. MEDLINE
  • 4
    McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339:14851492. MEDLINE
  • 5
    Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group. Lancet 1998; 352:14261432. MEDLINE
  • 6
    Choo QL, Kuo G, Ralston R, Weiner A, Chien D, Van Nest G, Han J, et al. Vaccination of chimpanzees against infection by the hepatitis C virus. Proc Natl Acad Sci U S A 1994; 91:12941298. MEDLINE
  • 7
    Houghton MC, Choo QL, Kuo G, Weiner A, Chien D, Ralston R, Urdea M, et al. Prospects for prophylactic and therapeutic C virus vaccines. Princess Takamatsu Symp 1995; 25:237243. MEDLINE
  • 8
    Houghton MC, Choo QL, Chien D, Kuo A, Weiner AJ, Coates S, Cousens L, et al. Development of an HCV vaccine. In: RizzettoM, PurcellRH, GerinJL, VermeG, eds. Viral Hepatitis and Liver Disease. Turin: Minerva Medica, 1997;656659.
  • 9
    Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, Petracca R, Weiner AJ, et al. Binding of hepatitis C virus to CD81. Science 1998; 282:938941. MEDLINE
  • 10
    Abrignani S, Rosa D. Perspectives for a hepatitis C virus vaccine. Clin Diagn Virol 1998; 10:181185. MEDLINE
  • 11
    Weiner AJ, Brauer MJ, Rosemblatt J, Richman KH, Tung J, Crawford K, Bonino F, et al. Variable and hypervariable domains are found in the regions of HCV corresponding to the flavivirus envelope and NS1 proteins and the pestivirus envelope glycoproteins. Virology 1991; 180:842848. MEDLINE
  • 12
    Martell M, Esteban JI, Quer J, Genescá J, Weiner A, Esteban R, Guardia J, et al. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasi species nature of HCV genome distribution. J Virol 1992; 66:32253229. MEDLINE
  • 13
    Martell M, Esteban JI, Quer J, Vargas V, Esteban R, Guardia J, Gomez J. Dynamic behavior of hepatitis C virus quasi species in patients undergoing orthotopic liver transplantation. J Virol 1994; 68:34253436. MEDLINE
  • 14
    Kurosaki M, Enomoto N, Marumo F, Sato C. Evolution and selection of hepatitis C virus variants in patients with chronic hepatitis C. Virology 1994; 205:161169. MEDLINE
  • 15
    Bukh J, Miller RH, Purcell RH. Genetic heterogeneity of hepatitis C virus: quasi species and genotypes. Semin Liver Dis 1995; 15:4163. MEDLINE
  • 16
    Weiner AJ, Geysen HM, Christopherson C, Hall JE, Mason TJ, Saracco G, Bonino F, et al. Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: potential role in chronic HCV infections. Proc Natl Acad Sci U S A 1992; 89:34683472. MEDLINE
  • 17
    Kato N, Sekiya H, Ootsuyama Y, Nakazawa T, Hijikata M, Ohkoshi S, Shimotohno K. Humoral immune response to hypervariable region 1 of the putative envelope glycoprotein (gp70) of hepatitis C virus. J Virol 1993; 67:39233930. MEDLINE
  • 18
    Kojima M, Osuga T, Tsuda F, Tanaka T, Okamoto H. Influence of antibodies to the hypervariable region of E2/NS1 glycoprotein on the selective replication of hepatitis C virus in chimpanzees. Virology 1994; 204:665672. MEDLINE
  • 19
    Shimizu YK, Hijikata M, Iwamoto A, Alter HJ, Purcell RH, Yoshikura H. Neutralizing antibodies against hepatitis C virus and the emergence of neutralization escape mutant viruses. J Virol 1994; 65:14941500.
  • 20
    Van Doorn L, Capriles I, Maertens G, DeLeys R, Murray K, Kos T, Schellekens H, et al. Sequence evolution of the hypervariable region in the putative envelope region E2/NS1 of hepatitis C virus is correlated with specific humoral immune responses. J Virol 1995; 69:773778. MEDLINE
  • 21
    Weiner A, Erickson AL, Kansopon J, Crawford K, Muchmore E, Hughes AL, Houghton M, et al. Persistent hepatitis C virus infection in a chimpanzee is associated with emergence of a cytotoxic T lymphocyte escape variant. Proc Natl Acad Sci U S A 1995; 92:27552759. MEDLINE
  • 22
    McAllister J, Casino F, Davidson J, Power E, Lawlor P, Yap L, Simmonds P, et al. Long-term evolution of the hypervariable region of hepatitis C virus in a common-source-infected cohort. J Virol 1998; 72:48934905. MEDLINE
  • 23
    Farci P, Shimoda A, Coiana A, Diaz G, Peddis G, Melpolder JC, Strazzera A, et al. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 2000; 288:339344. MEDLINE
  • 24
    Farci PA, Shimoda D, Wong T, Cabezon D, De Gioannis A, Strazzera A, Shimizu Y, et al. Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc Natl Acad Sci U S A 1996; 96:1539415399.
  • 25
    Puntoriero G, Meola A, Lahm A, Zucchelli S, Bruni Ercole B, Tafi R, Pezzanera M, et al. Towards a solution for hepatitis C virus hypervariability: mimotopes of the hypervariable region 1 can induce antibodies cross-reacting with a large number of viral variants. EMBO J 1998; 17:35213533. MEDLINE
  • 26
    Pessi A, Bianchi E, Bonelli F, Chiappinelli L. Application of the continuous-flow polyamide method to the solid-phase synthesis of a multiple antigen peptide (MAP) based on the sequence of a malaria epitope. J Chem Soc Chemical Communications 1990; 1:89.
  • 27
    Powell MF, Newman MJ. Vaccine Design, The Subunit and Adjuvant Approach. New York and London: Plenum Press, 1995;142.
  • 28
    Donnelly JJ, Ulmer JB, Liu MA. Immunization with DNA. Immunol Methods 1994; 176:145152.
  • 29
    Ulmer JB, Donnelly JJ, Deck RR, DeWitt CM, Liu MA. Immunization against viral proteins with naked DNA. Ann N Y Acad Sci 1995; 772:117125. MEDLINE
  • 30
    Liu MA. Overview of DNA Vaccines. Ann N Y Acad Sci 1995; 772:1520. MEDLINE
  • 31
    Calarota S, Bratt G, Nordlund S, Hinkula J, Leandersson AC, Sandstrom E, Wahren B. Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. Lancet 1998; 351:13201325. MEDLINE
  • 32
    Wang R, Doolan DL, Le TP, Hedstrom RC, Coonan KM, Charoenvit Y, Jones TR, et al. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 1998; 282:476480. MEDLINE
  • 33
    Ulmer JB, Donnelly JJ, Parker SE, Rhodes GH, Felgner PL, Dwarki VJ, Gromkowski SH, et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993; 259:17451749. MEDLINE
  • 34
    Sedegah M, Hedstrom R, Hobart P, Hoffman SL. Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein. Proc Natl Acad Sci U S A 1994,91:98669870.
  • 35
    Huygen K, Content J, Denis O, Montgomery DL, Yawman AM, Deck RR, DeWitt CM, et al. Immunogenicity and protective efficacy of a tuberculosis DNA vaccine. Nat Med 1996; 2:893898. MEDLINE
  • 36
    Boyer JD, Ugen KE, Wang B, Agadjanyan M, Gilbert L, Bagarazzi ML, Chattergoon M, et al. Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination. Nat Med 1997; 3:526532. MEDLINE
  • 37
    Davis HL, McCluskie MJ, Gerin JL, Purcell RH. DNA vaccine for hepatitis B: evidence for immunogenicity in chimpanzees and comparison with other vaccines. Proc Natl Acad Sci U S A 1996; 93:72137218. MEDLINE
  • 38
    Inchauspé G, Major ME, Nakano I, Vitvitski L, Trepo C. DNA vaccination for the induction of immune responses against hepatitis C virus proteins. Vaccine 1997; 15:853856. MEDLINE
  • 39
    Nakano I, Maertens G, Major ME, Vitvitski L, Dubuisson J, Fournillier A, De Martynoff G, et al. Immunization with plasmid DNA encoding hepatitis C virus envelope E2 antigenic domains induces antibodies whose immune reactivity is linked to the injection mode. J Virol 1997; 71:71017109. MEDLINE
  • 40
    Tedeschi V, Akatsuka T, Shih JW, Battegay M, Feinstone SM. A specific antibody response to HCV E2 elicited in mice by intramuscular inoculation of plasmid DNA containing coding sequences for E2. HEPATOLOGY 1997; 25:459462. MEDLINE
  • 41
    Lee SW, Cho JH, Lee KJ, Sung YC. Hepatitis C virus envelope DNA-based immunization elicits humoral and cellular immune responses. Mol Cells 1998a;8:444451.
  • 42
    Lee SW, Cho JH, Sung YC. Optimal induction of hepatitis C virus envelope-specific immunity by bicistronic plasmid DNA inoculation with the granulocyte-macrophage colony-stimulating factor gene. J Virol 1998b;72:84308436.
  • 43
    Howard CR, Gray L, D'Mello F, Christopher J, Craske J. Nucleic acid vaccines against hepatitis viruses. Dev Biol Stand 1998; 92:157162. MEDLINE
  • 44
    Fournillier A, Nakano I, Vitvitski L, Depla L, Vidalin O, Maertens G, Trepo C, et al. Modulation of immune responses to hepatitis C virus envelope E2 protein following injection of plasmid DNA using single or combined delivery routes. HEPATOLOGY 1998; 28:237244. MEDLINE
  • 45
    Fournillier A, Depla E, Karayiannis P, Vidalin O, Maertens G, Trepo C, Inchauspé G. Expression of noncovalent hepatitis C virus envelope E1-E2 complexes is not required for the induction of antibodies with neutralizing properties following DNA immunization. J Virol 1999; 73:74977504. MEDLINE
  • 46
    Forns X, Emerson SU, Tobin GJ, Mushahwar IK, Purcell RH, Buck J. DNA immunization of mice and macaques with plasmids encoding hepatitis C virus envelope E2 protein expressed intracellularly and on the cell surface. Vaccine 1999; 17:19922002. MEDLINE
  • 47
    Forns X, Payette PJ, Ma X, Satterfield W, Eder G, Mushahwar IK, Govindarajan S, et al. Vaccination of chimpanzees with plasmid DNA encoding the hepatitis C virus (HCV) envelope E2 protein modified the infection after challenge with homologous monoclonal HCV. HEPATOLOGY 2000; 32:618625. MEDLINE
  • 48
    Montgomery DL, Shiver JW, Leander KR, Perry HC, Friedman A, Martinez D, Ulmer JB, et al. Heterologous and homologous protection against influenza A by DNA vaccination: optimization of DNA vectors. DNA Cell Biol 1993; 12:777783. MEDLINE
  • 49
    Takamizawa A, Mori C, Fuke I, Manabe S, Murakami S, Fujita J, Onishi E, et al. Structure and organization of the hepatitis C virus genome isolated from human carriers. J Virol 1991; 65:11051113. MEDLINE
  • 50
    Nishihara T, Nozaki C, Nakatake H, Hoshiko K, Esumi M, Hayashi N, Hino K, et al. Secretion and purification of hepatitis C virus NS1 glycoprotein produced by recombinant baculovirus-infected insect cells. Gene 1993; 129:207214. MEDLINE
  • 51
    Cerino A, Boender P, La Monica N, Rosa C, Habets W, Mondelli MU. A human monoclonal antibody specific for the N terminus of the hepatitis C virus nucleocapsid protein. J Immunol 1993; 151:6700567015.
  • 52
    Casari G, Sander C, Valencia A. A method to predict functional residues in proteins. Nat Structural Biol 1995; 2:171178.
  • 53
    Cocquerel L, Meunier JC, Pillez A, Wychowski C, Dubuisson J. A retention signal necessary and sufficient for endoplasmic reticulum localization maps to the transmembrane domain of hepatitis C virus glycoprotein E2. J Virol 1998; 72:21832191. MEDLINE
  • 54
    Zucchelli S, Capone S, Fattori S, Folgori A, Di Marco A, Casimiro D, Simon AJ, et al. Enhancing B and T cell immune response to an HCV E2 DNA vaccine by muscle electro gene transfer. J Virol 2000; 74:1159811607. MEDLINE
  • 55
    Flint M, Dubuisson J, Maidens C, Harrop R, Guile GR, Borrow P, McKeating JA. Functional characterization of intracellular and secreted forms of a truncated hepatitis C virus E2 glycoprotein. J Virol 2000; 74:702709. MEDLINE
  • 56
    Forns X, Allander T, Rohwer-Nutter P, Buhk J. Characterization of modified hepatitis C virus E2 proteins expressed on the cell surface. Virology 2000; 274:7585. MEDLINE
  • 57
    Forns X, Payette PJ, Ma X, Satterfield W, Eder G, Mushahwar IK, Govindarajan S, et al. Vaccination of chimpanzees with plasmid DNA encoding the hepatitis C virus (HCV) envelope E2 protein modified the infection after challenge with homologous monoclonal HCV. HEPATOLOGY 2000; 32:618625. MEDLINE
  • 58
    Shirai M, Arichi T, Chen M, Masaki T, Nishioka M, Ikeda K, Takahashi H, et al. T cell recognition of hypervariable region-1 from hepatitis C virus envelope protein with multiple class II MHC molecules in mice and humans: preferential help for induction of antibodies to the hypervariable region. J Immunol 1999; 162:568576. MEDLINE
  • 59
    Rosa DS, Campagnoli C, Moretto E, Guenzi L, Cousens M, Chin C, Dong A, et al. A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells. Proc Natl Acad Sci U S A 1996; 93:17591763. MEDLINE
  • 60
    Abrignani S. Immune responses throughout hepatitis C virus (HCV) infection: HCV from the immune system point of view. Springer Semin Immunopathol 1997; 19:4755. MEDLINE
  • 61
    Deleersnyder V, Pillez A, Wychowski C, Blight K, Xu J, Hahn YS, Rice CM, et al. Formation of native hepatitis C virus glycoprotein complexes. J Virol 1997; 71:697704. MEDLINE
  • 62
    Zibert A, Kraas W, Meisel H, Jung G, Roggendorf M. 1Epitope mapping of antibodies directed against hypervariable region 1 in acute self-limiting and chronic infections due to hepatitis C virus. J Virol 1997; 71:41234127. MEDLINE
  • 63
    Patel A, Wood J, Penin F, Dubuisson J, McKeating J. Construction and characterization of chimeric E2 glycoprotein of hepatitis C virus: analysis of E2 regions interacting with CD81. J Gen Virol 2000; 81:28732883. MEDLINE